Jessica L Goren, PharmD. Instructor in Psychiatry, Cambridge Health Alliance.
Dr. Goren has no financial relationships with companies related to this material.
Learning Objectives
After reading this article, you should be able to:
1. Identify the primary medications used for treating obsessive-compulsive disorder (OCD).
2. Understand the importance of monitoring medication progress and communicating with prescribing professionals.
3. Demonstrate an understanding of evidence-based techniques for managing symptoms and improving functioning in clients with OCD.
As a psychotherapist treating a client with obsessive-compulsive disorder (OCD), you need to know which medications are typically prescribed along with common side effects. Cognitive behavioral therapy (CBT), including exposure and response prevention, is often the first choice for treating mild OCD (National Institute for Health Care Excellence (NICE), 2005 https://www.nice.org.uk/guidance/cg31); however, medication are usually necessary, either alone or in combination with CBT.
Selective serotonin reuptake inhibitors (SSRIs) are the primary medications for OCD. Currently, the following SSRIs are approved for treating OCD in the US (Soomro, G. M., Altman, D., Rajagopal, S., & Oakley-Browne, M. (2008). Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). The Cochrane database of systematic reviews, 2008(1), CD001765. https://doi.org/10.1002/14651858.CD001765.pub3):
Another option is clomipramine (Anafranil), a tricyclic antidepressant (TCA) with significant serotonin reuptake inhibition properties. However, due to its side effect profile, it is usually reserved for patients who have failed SSRI treatment.
It's crucial to remember that while medications can help, they rarely lead to complete remission of OCD symptoms. Most patients will not experience substantial improvement until at least four to six weeks after starting medication, and some may take up to 10 to 12 weeks (Koran LM and Simpson HB, Practice guideline for the treatment of patients with obsessive-compulsive disorder Guideline Watch March 2013).
If a patient doesn't respond to their first medication, you should ensure comorbid psychiatric illnesses are treated and consider adding CBT, switching to a different SSRI, or using clomipramine (Koran & Simpson, 2013).
For patients who have failed multiple treatments, augmentation strategies may be beneficial. These include pro-serotonergic agents (eg, buspirone, lithium); antipsychotics; and benzodiazepines. There's strong evidence for second-generation antipsychotics like aripiprazole (Abilify) or risperidone (Risperdal) as augmentation (Brakoulias, V., & Stockings, E. (2019). A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder. Expert opinion on pharmacotherapy, 20(1), 47–53. https://doi.org/10.1080/14656566.2018.1540590 ).
Although not used often, several other medications can be used for augmentation, including ondansetron (Zofran); memantine (Namenda); riluzole (Rilutek); low-dose clomipramine; lamotrigine; and mirtazapine (Remeron). For a list of medications discussed, see the table, “FDA-Approved Medications for OCD,” (below).
Nonpharmacologic treatments showing promise for OCD include neurosurgery; deep brain stimulation (DBS); electroconvulsive therapy (ECT); and transcranial magnetic stimulation (Koran, L. M., Hanna, G. L., Hollander, E., Nestadt, G., Simpson, H. B., & American Psychiatric Association (2007). Practice guideline for the treatment of patients with obsessive-compulsive disorder. The American journal of psychiatry, 164(7 Suppl), 5–53). However, these treatments are typically reserved for patients with severe, treatment-resistant OCD or those with comorbid depression.
As a psychotherapist, it's also important to be aware of potential side effects of the medications your clients may be taking. They may be sharing more with you about these side effects than they share with their prescribers, who often schedule relatively brief “med-check” visits. SSRIs can cause mild gastrointestinal effects, anxiety, agitation, insomnia, sexual dysfunction, weight gain, and QTc prolongation. Clomipramine, on the other hand, can cause anticholinergic side effects (which include dry mouth, dry eyes, constipation, and difficulty with urination), as well as cardiac toxicity.
Supporting medication treatment as a therapist
In addition to providing therapy to target your clients’ OCD symptoms, there are various ways you can help to enhance their response to medications.
FDA-Approved Medications for OCD | |
Medication (generic/brand) | Comments |
Clomipramine (Anafranil) | • Tricyclic antidepressant (TCA) that is also a nonselective serotonin reuptake inhibitor (SRI) • Limited data that suggest that it may a be more effective treatment for OCD than the selective serotonin reuptake inhibitors (SSRIs); however, it is associated with more side effects than SSRIs • Approved for adults and children aged 10 years and older with OCD • Can be fatal in overdose |
Fluoxetine (Prozac) | • SSRI • Because of long half-life, there is less likelihood of withdrawal effects due to missed doses • Approved for adults and children aged seven years and older with OCD |
Fluvoxamine (Luvox) | • SSRI • Approved for adults and children aged eight and older with OCD • Associated with many drug interactions |
Paroxetine (Paxil, Pexeva) | • SSRI • Stronger warnings against use in pregnancy* • Approved for adults, but not approved for pediatric patients with OCD |
Sertraline (Zoloft) | • SSRI • approved for adults and children aged six years and older with OCD |
*Notes on use during pregnancy: The strongest warnings are for paroxetine, which has been linked to congenital malformations (primarily cardiovascular) associated with exposure during the first trimester.
Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.
© 2024 Carlat Publishing, LLC and Affiliates, All Rights Reserved.